ABSTRACT
Background Major depressive disorder (MDD) is a debilitating illness characterized by the persistence of negative thoughts and emotions. Although antidepressant medications are effective, less than half of patients achieve complete remission despite multiple treatment trials. Repetitive transcranial magnetic stimulation (rTMS) has proven effective in the treatment of depression, especially for patients resistant to antidepressant medications. Remission rates when using rTMS for treatment-resistant depression (TRD) patients are between 30% and 40%. The responsiveness to pharmacotherapy and rTMS therapy may be influenced by genetic factors.
Objective Here we aim to characterize the genetic profile of refractory individuals with MDD and their rTMS responsiveness.
Methods We used an extreme-phenotype design (rTMS responders vs. non-responders) and conducted a genome wide association study on 48 participants and 593,260 SNPs.
Results We identified 53 significant SNP associations. Gene-set enrichment analysis showed that significantly associated genes loaded onto synaptic plasticity regulation pathways. Among the genes found differentially expressed in rTMS responders compared to non-responders were APP, GRID2 and SPPL2A genes.
Conclusions Based on these findings, we suggest that the identified genes may influence of rTMS responsiveness. Furthermore, the rTMS responsiveness may be associated with several pathways and not just to the influence of a single gene. To the best of our knowledge, this is the first report on the genetic profile of rTMS response using a GWAS approach. Nevertheless, further studies are necessary to enlight the molecular mechanism by which these genes affect response to rTMS treatment.
Competing Interest Statement
PBF has received equipment for research from Medtronic, MagVenture A/S and Brainsway Ltd. He is on scientific advisory boards for Bionomics Ltd and LivaNova and is a founder of TMS Clinics Australia.
Funding Statement
The study was supported by grants from the National Health and Medical Research Council (NHMRC) (1041890) and Alfred Hospital. PBF was supported by a Practitioner Fellowship grant from National Health and Medical Research Council (NHMRC) (1078567). NGSS was supported by a scholarship from CAPES-Brazil. KEH was supported by an NHMRC Fellowship (1135558). MAB was supported by a Senior Research Fellowship (level B) from the NHMRC (1154378). MARS and DMM were supported by Research Fellowships from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)-Brazil and a CAPES-PGCI grant (47/2014).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Our ethics approval does not allow data sharing.